RespireRx Pharmaceuticals Inc. a company focused on the discovery and development of treatments to combat diseases caused by disruption of neuronal signaling, and ResolutionRx Ltd., entered into a master services agreement with Ab Initio Pharma Pty Ltd, under which Ab Initio will manufacture, formulate, test and supply ResolutionRx with therapeutic drugs based on lipid nanoparticle technology licensed from RespireRx. The initial services relate to ResolutionRx’s repurposing of dronabinol and ...